DP
GMAB icon

DDD Partners’s Genmab GMAB Stock Holding History

DDD Partners’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-601,050
Closed -$11.8M – 117
2025
Q1 		$11.8M Buy
601,050
+374,976
+166% +$7.87M 1.43% 31
2024
Q4 		$4.72M Sell
226,074
-357,039
-61% -$7.84M 0.58% 39
2024
Q3 		$14.2M Buy
583,113
+230,544
+65% +$6.16M 1.54% 32
2024
Q2 		$8.86M Buy
+352,569
New +$10M 1.03% 35

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

DDD Partners's GMAB Position: Q2 2025 in Review

DDD Partners sold out of Genmab (GMAB) in Q2 2025, closing a stake of 601,050 shares — an estimated $11.8M sold.

DDD Partners first reported a position in GMAB in Q2 2024 and held it in 4 quarters. The position peaked at $14.2M in Q3 2024. 217 funds tracked by Wall St. Rank hold GMAB as of Q2 2025.

  • DDD Partners reported no remaining Genmab position as of Q2 2025 after selling out during the quarter.
  • DDD Partners sold 601,050 Genmab shares in Q2 2025, an estimated $11.8M.
  • DDD Partners first reported a position in Genmab in Q2 2024 and held it in 4 quarters.
  • DDD Partners's Genmab position peaked at $14.2M in Q3 2024.
  • 217 funds tracked by Wall St. Rank held Genmab as of Q2 2025.

Based on DDD Partners's 13F filing for Q2 2025, filed 31 Jul 2025.